E. V. Chernyaeva

Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults.

Andrey Pristrom, Nikolay Soroka, P. А. Shesternya et al. · PubMed · 2020 · 40 citations

THE RESULTS OF A PHASE III COMPARATIVE CLINICAL TRIAL OF RITUXIMAB (ACELLBIA® AND MABTHERA®) IN RHEUMATOID ARTHRITIS (THE BIORA STUDY)

E L Nasonov, L. A. Knyazeva, Mazurov Vi et al. · Rheumatology Science and Practice · 2016 · 31 citations · Full text

DEVELOPMENTS OF RUSSIAN ORIGINAL BIOLOGICAL AGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY RHEUMATIC DISEASES

E L Nasonov, V. I. Mazurov, Yu. V. Usacheva et al. · Rheumatology Science and Practice · 2017 · 27 citations · Full text

Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis

E. V. Sokolovskiy, A. V. Artemyeva, E. V. Chernyaeva et al. · Vestnik dermatologii i venerologii · 2019 · 22 citations · Full text

Immunology, Original Monoclonal Antibody, Pharmacotherapy +19

Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext

A. V. Artemyeva, S. I. Derbin, E. V. Chernyaeva et al. · Vestnik dermatologii i venerologii · 2019 · 17 citations · Full text

Adverse Events, Autoimmune Disease, Allergy +11